Graphene quantum dots prevent alpha-synucleinopathy in Parkinson's disease
Authors:
Donghoon Kim,
Je Min Yoo,
Heehong Hwang,
Junghee Lee,
Su Hyun Lee,
Seung Pil Yun,
Myung ** Park,
MinJun Lee,
Seulah Choi,
Sang Ho Kwon,
Saebom Lee,
Seung-Hwan Kwon,
Sangjune Kim,
Yong Joo Park,
Misaki Kinoshita,
Young-Ho Lee,
Seokmin Shin,
Seung R. Paik,
Sung Joong Lee,
Seulki Lee,
Byung Hee Hong,
Han Seok Ko
Abstract:
While the emerging evidence indicates that the pathogenesis of Parkinson's disease (PD) is strongly correlated to the accumulation of alpha-synuclein (α-syn) aggregates, there has been no clinical success in anti-aggregation agents for the disease to date. Here we show that graphene quantum dots (GQDs) exhibit anti-amyloid activity via direct interaction with α-syn. Employing biophysical, biochemi…
▽ More
While the emerging evidence indicates that the pathogenesis of Parkinson's disease (PD) is strongly correlated to the accumulation of alpha-synuclein (α-syn) aggregates, there has been no clinical success in anti-aggregation agents for the disease to date. Here we show that graphene quantum dots (GQDs) exhibit anti-amyloid activity via direct interaction with α-syn. Employing biophysical, biochemical, and cell-based assays as well as molecular dynamics (MD) simulation, we find that GQDs have notable potency in not only inhibiting fibrillization of α-syn but also disaggregating mature fibrils in a time-dependent manner. Remarkably, GQDs rescue neuronal death and synaptic loss, reduce Lewy body (LB)/Lewy neurite (LN) formation, ameliorate mitochondrial dysfunctions, and prevent neuron-to-neuron transmission of α-syn pathology induced by α-syn preformed fibrils (PFFs) in neurons. In addition, in vivo administration of GQDs protects against α-syn PFFs-induced loss of dopamine neurons, LB/LN pathology, and behavioural deficits through the penetration of the blood-brain barrier (BBB). The finding that GQDs function as an anti-aggregation agent provides a promising novel therapeutic target for the treatment of PD and related α-synucleinopathies.
△ Less
Submitted 9 July, 2018; v1 submitted 17 October, 2017;
originally announced October 2017.
